The Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market size is estimated at USD 117.23 million in 2023, and is expected to reach USD 166.43 million by 2028, growing at a CAGR of 7.26% during the forecast period (2023-2028).
The market is estimated to reach a value of more than USD 160 million by 2027.
The COVID-19 pandemic positively impacted the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over sulfonylureas or meglitinides is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes' composition. Therefore, GLP-1RAs have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.
73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region are living with Impaired Glucose Tolerance, which places them at increased risk of developing type 2 diabetes. Diabetes is responsible for 796,000 deaths in the IDF MENA Region in 2021. USD 33 billion was spent on healthcare for people with diabetes in 2021.
The Middle East and African region had witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
GLP1RAs are available internationally and are now recommended for use when treatment escalation for type 2 diabetes is required after metformin and lifestyle management. They can be safely used with all other glucose-lowering therapies except vildagliptin. Dulaglutide (Trulicity) is a weekly subcutaneous GLP1RA that reduces HbA1c with additional weight loss and cardiorenal protection benefits. Therapy with dulaglutide allows many patients to reach and maintain target HbA1c without insulin and/or sulfonylureas, eliminating the associated hypoglycemia risk. GLP1RAs elicit greater weight reduction and are recommended over SLGT2 inhibitors when cerebrovascular disease other than heart failure or renal disease predominates.
The UAE Ministry of Health granted the marketing authorization for Lilly’s Trulicity (dulaglutide) solution for injection. It is a once-weekly, injectable solution designed to improve glycemic control in adults with type 2 diabetes. Trulicity (dulaglutide) also reduces the risk of non-fatal stroke in adults with type 2 diabetes mellitus. It is for those with multiple cardiovascular risk factors or established cardiovascular disease as an adjunct to diet, exercise, and standard-of-care therapy. This decision made Eli Lilly and Company’s Trulicity the first and only GLP1 receptor agonist approved to provide a cardiovascular benefit in people with multiple CV risk factors or with established cardiovascular disease.
Governments in the Middle East identified the threat of diabetes and started to respond with various policies, initiatives, and programs. Six out of 15 countries in this region still do not include a national operational action policy for diabetes. Many countries still do not contain a national strategy to reduce overweight, obesity, and physical inactivity, which are important risk factors for diabetes. Most counties fully implemented national diabetes treatment guidelines. However, constant measures are being taken to minimize diabetic complications.
The market will likely continue to grow due to the rising rate of obesity, the increasing prevalence, and the factors mentioned above.
More than one in ten people in Saudi Arabia is living with diabetes, and the prevalence of the disease will almost double by 2045, according to a report by the International Diabetes Federation. The report mentioned that 4.27 million people in Saudi Arabia include diabetes. This figure will increase to 5.6 million by 2030. Glucagon-like peptide-1 receptor agonists are a class of prescription medications effective in treating type 2 diabetes. In addition to lowering blood glucose levels to help treat type 2 diabetes, GLP-1 agonists also result in weight loss and other metabolic health benefits. GLP-1 medications are safe, effective and come with relatively few side effects. Any common side effects that patients may experience while taking GLP-1s, such as nausea, are manageable.
There are constant innovations and studies relating to drug molecules or formulation technologies. For instance, Hanmi Pharmaceutical stated in September 2021 announced that its new, long-acting diabetes biologic drug, efpeglenatide (GLP-1 RA), was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease. It results from its global, large-scale clinical trial with more than 4,000 patients adding to the drug's efficacy.
Saudi Government, in July 2022, announced that Saudi Arabia saw growing demand for quality healthcare services spurred by changes. It includes an increasing aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity. The government and private sector are involved in working on healthcare entities, certifications, and regulations. The government is taking steps to include 100% of Saudi citizens covered by insurance. They are working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.
Owing to the factors above, the market is expected to grow during the forecast period.
The market is estimated to reach a value of more than USD 160 million by 2027.
The COVID-19 pandemic positively impacted the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over sulfonylureas or meglitinides is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes' composition. Therefore, GLP-1RAs have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.
73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region are living with Impaired Glucose Tolerance, which places them at increased risk of developing type 2 diabetes. Diabetes is responsible for 796,000 deaths in the IDF MENA Region in 2021. USD 33 billion was spent on healthcare for people with diabetes in 2021.
The Middle East and African region had witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends
Dulaglutide Segment held the highest market share in the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year
The Dulaglutide segment held the highest market share of about 58% in the Middle East and the African Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year.GLP1RAs are available internationally and are now recommended for use when treatment escalation for type 2 diabetes is required after metformin and lifestyle management. They can be safely used with all other glucose-lowering therapies except vildagliptin. Dulaglutide (Trulicity) is a weekly subcutaneous GLP1RA that reduces HbA1c with additional weight loss and cardiorenal protection benefits. Therapy with dulaglutide allows many patients to reach and maintain target HbA1c without insulin and/or sulfonylureas, eliminating the associated hypoglycemia risk. GLP1RAs elicit greater weight reduction and are recommended over SLGT2 inhibitors when cerebrovascular disease other than heart failure or renal disease predominates.
The UAE Ministry of Health granted the marketing authorization for Lilly’s Trulicity (dulaglutide) solution for injection. It is a once-weekly, injectable solution designed to improve glycemic control in adults with type 2 diabetes. Trulicity (dulaglutide) also reduces the risk of non-fatal stroke in adults with type 2 diabetes mellitus. It is for those with multiple cardiovascular risk factors or established cardiovascular disease as an adjunct to diet, exercise, and standard-of-care therapy. This decision made Eli Lilly and Company’s Trulicity the first and only GLP1 receptor agonist approved to provide a cardiovascular benefit in people with multiple CV risk factors or with established cardiovascular disease.
Governments in the Middle East identified the threat of diabetes and started to respond with various policies, initiatives, and programs. Six out of 15 countries in this region still do not include a national operational action policy for diabetes. Many countries still do not contain a national strategy to reduce overweight, obesity, and physical inactivity, which are important risk factors for diabetes. Most counties fully implemented national diabetes treatment guidelines. However, constant measures are being taken to minimize diabetic complications.
The market will likely continue to grow due to the rising rate of obesity, the increasing prevalence, and the factors mentioned above.
Saudi Arabia held the highest market share in the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year
Saudi Arabia held the highest market share of about 30% in the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year.More than one in ten people in Saudi Arabia is living with diabetes, and the prevalence of the disease will almost double by 2045, according to a report by the International Diabetes Federation. The report mentioned that 4.27 million people in Saudi Arabia include diabetes. This figure will increase to 5.6 million by 2030. Glucagon-like peptide-1 receptor agonists are a class of prescription medications effective in treating type 2 diabetes. In addition to lowering blood glucose levels to help treat type 2 diabetes, GLP-1 agonists also result in weight loss and other metabolic health benefits. GLP-1 medications are safe, effective and come with relatively few side effects. Any common side effects that patients may experience while taking GLP-1s, such as nausea, are manageable.
There are constant innovations and studies relating to drug molecules or formulation technologies. For instance, Hanmi Pharmaceutical stated in September 2021 announced that its new, long-acting diabetes biologic drug, efpeglenatide (GLP-1 RA), was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease. It results from its global, large-scale clinical trial with more than 4,000 patients adding to the drug's efficacy.
Saudi Government, in July 2022, announced that Saudi Arabia saw growing demand for quality healthcare services spurred by changes. It includes an increasing aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity. The government and private sector are involved in working on healthcare entities, certifications, and regulations. The government is taking steps to include 100% of Saudi citizens covered by insurance. They are working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.
Owing to the factors above, the market is expected to grow during the forecast period.
Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Industry Overview
The Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market is consolidated, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca, holding their presence in all regions.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 MARKET INDICATORS
7 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk
- AstraZeneca
- Eli Lilly and Company
- Sanofi
- Pfizer
Methodology
LOADING...
